Under brand names like Ozempic and Wegovy, semaglutide-based medications have made a significant difference in treating type ...

Antibe Therapeutics named Yung Wu to its board of directors and completed enrollment for its phase 2 clinical trial.

The CALMA trial is a multicenter, double-blind, randomized, placebo-controlled Phase 2 study involving 164 participants. It is designed to evaluate the safety and efficacy of IGC-AD1, a partial ...

IGC Pharma (IGC) announced that its ongoing Phase 2 trial for agitation in Alzheimer’s disease has been officially named CALMA. The trial’s new identity reflects its mission to address ...

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer’s Agitation “CALMA” and Expands Recruitment Strategy ...

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy ...